(ChatterShmatter) – A new experimental drug has shown a lot of promise in treating the early stages of cystic fibrosis.
Denufosol is the name of the new drug and when compared over a six-month period against a placebo in young children those who received it had decreased lung damage.
The drug works by helping to prevent the formation of the sticky mucus that clogs up the lungs of CF patients, making it difficult to breathe.
352 participants were enrolled in the drug trial, all of whom at least five years of age or older.
“Although the lungs of children with CF are thought to be normal at birth, studies have demonstrated significant lung damage that occurs early in life in children suffering from cystic fibrosis,” said lead investigator Frank Accurso, professor of pediatrics, University of Colorado School of Medicine, Denver.
“Many patients continue to suffer progressive loss of lung function despite treatment of complications. Because denufosol can be used early in life, it offers hope for delaying or preventing the progressive changes that lead to irreversible airflow obstruction in CF patients.”